semaglutide and cancer risk GLP-1 use linked to better survival rates in colorectal cancer

GLP-1 drugs and cancer: the headline is exciting. The full picture is more nuanced. New research from @ascocancer 2026 shows patients on GLP-1 medications like semaglutide were up to 50% less likely

28.43

★★★★☆4.8 (126)

New Research Challenges Fears of Semaglutide-Linked Thyroid Cancer Risk

26.78

★★★★★4.9 (98)

Semaglutide 2.4 mg delivered a statistically significant 20% risk reduction in major adverse cardiovascular events – REGENHEALTHSOLUTIONS (RHS)

20.86

★★★★★5.0 (157)

VisualAbstract:Oral semaglutide effectively reduces bodyweight in non-diabetic adults with obesity

28.85

★★★★★4.7 (84)

In a major new JAMA Oncology study, researchers examined health records from 86,632 adults with obesity, comparing those who used GLP-1 receptor agonists (like semaglutide or tirzepatide) to matched non-users. The findings

23.76

★★★★★4.9 (203)

Weight-Loss Drugs May Have Surprising Side Effect: Stalling Cancer

21.90

★★★★★5.0 (176)

Could GLP-1 medications play a role in reducing breast cancer recurrence risk? In a story for Oprah Daily, Melinda Irwin, PhD, MPH, explains that weight management can improve inflammation, metabolism, immune function,

20.13

★★★★★4.8 (132)